Table 1 Correlations between clinicopathological characteristics of patients and LNM in the training and validation sets
Characteristics | Training Cohort | Validation set | ||||
|---|---|---|---|---|---|---|
LNM- | LNM+ | P value | LNM- | LNM+ | P value | |
Median number of retrieved LN (IQR) | 2 (1–5) | / | 2 (1–4) | / | ||
Age | ||||||
≤ 60 | 103 (29.0%) | 54 (26.3%) | 0.561 | 40 (27.0%) | 21 (23.9%) | 0.702 |
>60 | 252 (71.0%) | 151 (73.7%) | 108 (73.0%) | 67 (76.1%) | ||
Gender | ||||||
Male | 112 (31.5%) | 52 (25.3%) | 0.121 | 46 (31.1%) | 18 (20.5%) | 0.076 |
Female | 243 (68.5%) | 153 (74.6%) | 102 (68.9%) | 70 (79.5%) | ||
Race | ||||||
White | 249 (70.1%) | 157 (76.6%) | 0.214 | 108 (73.0%) | 66 (75.0%) | 0.456 |
Black | 50 (14.1%) | 20 (9.8%) | 19 (12.8%) | 14 (15.9%) | ||
Others | 56 (15.8%) | 28 (13.7%) | 21 (14.2%) | 8 (9.1%) | ||
Histology | ||||||
Adenocarcinoma | 346 (97.5%) | 203 (99.0%) | 0.343* | 147 (99.3%) | 88 (100.0%) | 0.999* |
Squamous cell carcinoma | 9 (2.5%) | 2 (1.0%) | 1 (0.7%) | 0 (0.0%) | ||
Grade | ||||||
Well differentiated | 87 (24.5%) | 26 (12.7%) | < 0.001 | 39 (26.4%) | 11 (12.5%) | 0.008 |
Moderately differentiated | 181 (51.0%) | 96 (46.8%) | 71 (48.0%) | 40 (45.5%) | ||
Poorly/un- differentiated | 87 (24.5%) | 83 (40.5%) | 38 (25.7%) | 37 (42.0%) | ||
T stage | ||||||
T1a | 38 (10.7%) | 2 (1.0%) | < 0.001 | 15 (10.1%) | 2 (2.3%) | < 0.001 |
T1b | 75 (21.1%) | 8 (3.9%) | 29 (19.6%) | 5 (5.7%) | ||
T2 | 242 (68.2%) | 195 (95.1%) | 104 (70.3%) | 81 (92.0%) | ||
Tumor size | ||||||
≤ 1 cm | 67 (18.9%) | 10 (4.9%) | < 0.001 | 34 (23.0%) | 5 (5.7%) | 0.005 |
>1 cm | 288 (81.1%) | 195 (95.1%) | 114 (77.0%) | 21 (94.3%) | ||